Page last updated: 2024-11-07

acetylneurotensin (8-13)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

acetylneurotensin (8-13): shortest analog with full binding & pharmacological activities [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID156313
MeSH IDM0106684

Synonyms (10)

Synonym
(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic a
acetylneurotensin (8-13)
n-acetyl-neurotensin-(8-13)
l-leucine, n-(n-(n-(1-(n2-(n2-acetyl-l-arginyl)-l-arginyl)-l-prolyl)-l-tyrosyl)-l-isoleucyl)-
74853-69-3
mfcd00076687
acetyl-neurotensin (8-13) (ac-l-arg-l-arg-l-pro-l-tyr-l-ile-l-leu-oh)
CS-0653204
acetyl neurotensin(8-13)
HY-P4223
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's6 (85.71)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.01 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]